Disc Medicine Inc. has released a corporate presentation detailing the progress of their investigational agents, Bitopertin, DISC-0974, and DISC-3405. The presentation outlines updates on the clinical programs, including the NDA progress for Bitopertin in Erythropoietic Protoporphyria $(EPP.UK)$, the MF Anemia Phase 1b data for DISC-0974, and the Phase 2 study design for DISC-3405 in Polycythemia Vera. Additionally, the presentation includes insights into the commercialization planning and the potential for accelerated approval for certain programs. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief on June 16, 2025, and is solely responsible for the information contained therein.